19:35 , Jan 18, 2019 |  BioCentury  |  Emerging Company Profile

Achilles’ truncal neoantigens

Achilles Therapeutics Ltd. is developing a personalized T cell therapy that uses “truncal” neoantigens expressed in all tumor cells to drive T cells selected from tumor-infiltrating lymphocytes (TILs). Neoantigen discovery is fueling a burst of...
04:20 , Dec 21, 2018 |  BC Innovations  |  Product R&D

Cell therapies seek solid ground

To make cell therapies work in solid tumors, drug companies will have to either master combination therapies or figure out how to make their treatments trigger broad immune responses that extend beyond the antigen specificity...
18:56 , Dec 13, 2018 |  BC Innovations  |  Translation in Brief

3-D immune response

A Boston Children's Hospital team has developed a 3-D human tissue model that reproduces age-specific immune responses to vaccine antigens and could surmount the hurdles of developing vaccines for neonates and infants. Preclinical vaccine development...
16:11 , Dec 12, 2018 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model could help predict immune responses to vaccines. Generation and use of the model involves: placing a single layer of donor-derived human umbilical vein endothelial cells (HUVECs) over...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest a vaccine based on a tetanus toxoid-MUC1 conjugate could help treat MUC1-expressing breast cancer. The conjugate consists of a 22-mer human MUC1 peptide conjugated to tetanus toxoid carrier protein,...
22:56 , Dec 5, 2018 |  BC Extra  |  Tools & Techniques

Proteogenomic screen identifies non-mutated tumor-specific antigens

A University of Montreal team has developed a proteogenomic screen that identifies mutated and non-mutated tumor-specific TCR antigens, including those arising from normally non-coding nucleotide sequences. The technique could help develop T cell immunotherapies targeting...
03:50 , Dec 1, 2018 |  BioCentury  |  Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
20:11 , Nov 26, 2018 |  BC Innovations  |  Distillery Therapeutics

Transplant

INDICATION: Heart transplant rejection Mouse studies suggest APOA/phospholipid-based nanoparticles loaded with rapamycin or a TRAF6 inhibitor could help prevent heart transplant rejection. The nanoparticles consist of APOA and natural phospholipid components of HDL cholesterol isolated...
03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...